Verdict No. 1003 · Search date 2026-07-21 · Methodology v0.6
Estazolam is a benzodiazepine hypnotic and sedative available by prescription and controlled as a psychotropic medicine.,
does it really help with The claim is short-term improvement in sleep onset, sleep maintenance, and sleep duration in adults with insomnia.?
30-Second Summary
C
Evidence Grade C · 55 · Safety unknown
Estazolam can improve some short-term sleep symptoms, but objective and long-term evidence is limited, and its safety burden is a separate issue.
What the
research showsPlacebo-controlled trials lasting about seven nights found improvements in subjective sleep duration and nocturnal awakenings, but sleep-onset results varied by dose and trial. No adequate randomized evidence establishing sustained long-term benefit was identified.
research showsPlacebo-controlled trials lasting about seven nights found improvements in subjective sleep duration and nocturnal awakenings, but sleep-onset results varied by dose and trial. No adequate randomized evidence establishing sustained long-term benefit was identified.
What the
ads claimClaims that it treats insomnia or restores sound sleep may imply proven sustained benefit and functional recovery. This verdict addresses only short-term symptom effects.
ads claimClaims that it treats insomnia or restores sound sleep may imply proven sustained benefit and functional recovery. This verdict addresses only short-term symptom effects.
Useful facts when choosing a product
- Estazolam is a prescription benzodiazepine hypnotic and sedative regulated as a controlled psychotropic medicine.
- The pivotal trials reviewed mainly lasted seven nights, so their findings cannot establish long-term insomnia benefit.
- Dose, comorbidity, older age, and concomitant medicines can alter next-day sedation and fall risk.
- Marketing authorization and availability do not determine evidence strength, and use should follow prescribing information and clinical supervision.
Gap Measurement · Verdict 1003 · C 55
What the research actually shows
Research supports a short-term efficacy signal but lacks modern large trials with low risk of bias, long follow-up, and robust objective sleep measures.
Why this is classified as C (55)
Placebo-controlled randomized trials repeatedly found short-term subjective improvements in sleep maintenance and duration, but sleep-onset effects were inconsistent and the objective polysomnography trial enrolled only 15 participants. The AASM could not make a recommendation, so subjective-outcome boundary rule 1 fixes the result at C with 55 points.
Counterpoint. Even a small average effect may matter to someone with severe short-term insomnia. That potential clinical value must still be weighed separately against dependence, withdrawal, and next-day impairment.
Rejudgment record. Cross-validation incorporated — The direct symptom outcomes in short placebo-controlled trials were credited, but subjective assessment dominated, the polysomnography trial enrolled 15 participants, and the AASM found the evidence inadequate for quantitative synthesis and clinical-significance judgments; boundary rule 1 was therefore applied.
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Short-term improvement in sleep onset | C | Subjective sleep onset improved with 2 mg, but not significantly with 1 mg or in the 15-participant objective trial, limiting consistency. |
| Short-term improvement in sleep maintenance and duration | C | Several seven-night placebo-controlled trials and a small polysomnography study found fewer nocturnal awakenings and longer total sleep time. |
| Short-term increase in total sleep time | C | Seven-night subjective assessments and a 15-participant polysomnography study found longer total sleep time, but the objective evidence base is very small. |
Cross-check — Codex and Claude
This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Seven-night double-blind randomized trial assigning outpatients with insomnia to estazolam 2 mg, flurazepam 30 mg, or placebo | 229 | Funding not stated in the abstract | Subjective sleep latency, nocturnal awakenings, total sleep time, and global improvement | Moderate or marked global improvement was reported by 81% with estazolam and 36% with placebo, with advantages on several subjective sleep measures. | Direct randomized comparison, but only seven nights and dominated by subjective measures |
| Study 2 | Seven-night multicenter double-blind randomized trial of estazolam 1 mg, estazolam 2 mg, flurazepam, or placebo | 223 | Funding not stated in the abstract | Subjective sleep latency, total sleep time, nocturnal awakenings, and sleep quality | The 2 mg dose outperformed placebo on the principal sleep measures, whereas 1 mg did not significantly improve sleep latency. | Short randomized trial demonstrating dose-dependent limits to consistency |
| Study 3 | Objective polysomnographic trial comparing placebo with multiple estazolam doses in patients with insomnia | 15 | Funding not stated in the abstract | Total sleep time, wake time during sleep, and sleep latency | Total sleep time and wake time during sleep improved in a dose-related fashion, but the sleep-latency difference was not significant. | Objective measurement is a strength, but the sample of 15 is highly limiting |
| Study 4 | Systematic evidence assessment and recommendations for pharmacologic treatment of chronic insomnia in adults | 3 | American Academy of Sleep Medicine | Quantitative synthesis and clinical significance for sleep quality, onset, and maintenance | The evidence was unsuitable for meta-analysis and clinical-significance assessment, so no recommendation for estazolam was made. | Independent guideline assessment confirming structural evidence limitations |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-21).
Scharf MB, Roth PB, Dominguez RA, Ware JC. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia. J Clin Pharmacol. 1990;30(5):461-467. PMID: 1971831. DOI: 10.1002/j.1552-4604.1990.tb03486.x.
checkedCohn JB, Wilcox CS, Bremner J, Ettinger M. Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. J Clin Pharmacol. 1991;31(8):747-750. DOI: 10.1002/j.1552-4604.1991.tb03771.x.
checkedRoehrs T, Zorick F, Lord N, Koshorek GL, Roth T. Dose-related effects of estazolam on sleep of patients with insomnia. J Clin Psychopharmacol. 1983;3(3):152-156. DOI: 10.1097/00004714-198306000-00002.
checkedSateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307-349. PMID: 27998379. PMCID: PMC5263087. DOI: 10.5664/jcsm.6470.
checkedDraft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Does estazolam improve short-term sleep in adults with insomnia? — Evidence Grade C·55. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/estazolam-short-term-insomnia-sleep-onset-maintenance-duration/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.